¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific cellular immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • humoral immunity
    ü¾×¸é¿ª
  • immunity
    1. ¸é¿ª 2. ¸é¿ª¼º
  • individual immunity
    °³Àθ鿪, °³Ã¼¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • native immunity
    °íÀ¯¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • protective immunity
    ¹æ¾î¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
  • racial immunity
    ÀÎÁ¾¸é¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cross immunity
    ±³Â÷¸é¿ª
  • gut immunity
    âÀڸ鿪, Àå°ü¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª, ¹«¸®¸é¿ª
  • humoral immunity
    ü¾×¸é¿ª
  • immunity
    ¸é¿ª
  • infection immunity
    °¨¿°¸é¿ª
  • innate immunity
    ¼±Ãµ¸é¿ª
  • local immunity
    ±¹¼Ò¸é¿ª
  • maternal immunity
    ¸ð¼º¸é¿ª
  • native immunity
    (¢¡innate immunity) ¼±Ãµ¸é¿ª
  • natural immunity
    ÀÚ¿¬¸é¿ª
  • nonspecific immunity
    ºñƯÀ̸鿪
  • opsonic immunity
    ¿É¼Ò´Ñ¸é¿ª
  • passive immunity
    ¼öµ¿¸é¿ª
  • permanent immunity
    ¿µ±¸¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antimicrobial immunity
    Çױո鿪(¡­Øóæ¹).
  • antitoxic immunity
    Ç×µ¶(¼Ò)¼º ¸é¿ª(ù÷Ô¸áÈàõØóæ¹).
  • antitumor immunity
    Ç×Á¾¾ç(¼º) ¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(¡­Øóæ¹).
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º¸é¿ª(~Øóæ¹)
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª.
  • gut immunity
    Àå°ü¸é¿ª
  • herd immunity
    ±ºÁý¸é¿ª, Áý´Ü¸é¿ª
  • herd immunity
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, cross
    ±³Â÷¸é¿ª
  • immunity, gut
    Àå°ü¸é¿ª
  • immunity, herd
    Áý´Ü¸é¿ª, ±ºÁý¸é¿ª, ¹«¸®¸é¿ª
  • immunity, humoral
    ü¾×¼º¸é¿ª
  • immunity, innate
    ¼±Ãµ¸é¿ª
  • immunity, local
    ±¹¼Ò¸é¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cellular response
    ¼¼Æ÷¼º¹ÝÀÀ
  • cellular retinoid acid-bindin gprotein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê°áÇմܹé(¡­Ì¿ùêÓ±ÛÜ)
  • cellular retinol-binding protein
    ¼¼Æ÷³» ·¹Æ¼³î °áÇմܹé
  • cellular sensitivity
    ¼¼Æ÷°¨¼ö¼º
  • cellular type dermatofibroma
    ¼¼Æ÷Çü ÇǺμ¶À¯Á¾
  • death, cellular (molecular)
    ¼¼Æ÷»ç¸Á, ¼¼Æ÷»ç
  • degeneration, cellular
    º¯¼º, ¼¼Æ÷¼º(á¬øààõ)
  • division, cellular
    ¼¼Æ÷ºÐ¿­
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • hypersensitivity, cellular
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
  • ischemia, cellular
    ±¹¼ÒºóÇ÷(ÇãÇ÷), ¼¼Æ÷¼º(á¬øààõ)
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • toxic injury, cellular
    µ¶¼º »óÇØ(¼Õ»ó), ¼¼Æ÷¼º
  • werner syndrome,cellular senescence in
    ¡­ÀÇ ¼¼Æ÷¼º ³ëÈ­
  • acquired immunity
    ÈÄõ¼º ¸é¿ª, ½Å°æÈ¹µæ¸é¿ª(üòÔðØóæ¹).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • site-specific inversion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ¿ªÀ§(æ½êÈ)
  • site-specific recombinstion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • specific acid-base catalysis
    ƯÀÌ »ê.¿°±â Ã˸Å(÷åì¶ß«ç¤ÐñõºØÚ)
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
  • specific adsorption
    ¼±ÅÃÈíÂø(àÔ÷Éýåó·)
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
  • specific rate constant
    ƯÀÌ ¼Óµµ»ó¼ö(÷åì¶áÜÓøßÈâ¦)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
HCC Hepato-Cellular Cacinoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
c-SRC Cellular SRC
CAM Cellular adhesion molecules
CFA Cellular fatty acid
cFN Cellular fibronectin
c-onc cellular oncogene
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular detection
    ¼¼Æ÷ °ËÃâ
    ¼¼Æ÷ÀÇ Á¸À縦 °ËÃâÇÏ´Â °Í.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cellular infiltration
    ¼¼Æ÷ ħÀ±
    ¼¼Æ÷°¡ ħÀ±¿¡ ÀÇÇÏ¿© Ä§ÂøµÈ °Í.
  • cellular invagination
    ¼¼Æ÷ ÇÔÀÔ
    ¼¼Æ÷ÀÇ ¾î¶² ºÎºÐÀÌ ´Ù¸¥ ºÎºÐ³»¿¡ ÇÔÀÔÇÏ´Â °Í.
  • cellular layer
    ¼¼Æ÷ Ãþ
    ¼¼Æ÷°¡ °ÅÀÇ ÀÏÁ¤ÇÑ µÎ²²ÀÇ, ȬÀ̺Ҹð¾çÀÇ Á¶Á÷ ±¸Á¶¸¦ °¡Áö´Â °Í.
  • cellular membrane
    ¼¼Æ÷¼º ¸·
    ¼¼Æ÷ÀÇ Ç¥¸éÀ» µ¤°Å³ª °øµ¿ÀÇ ³»¸éÀ» µ¤´Â, ¶Ç´Â °ø°£À̳ª ±â°üÀ» ³ª´©´Â ¾ãÀº ÃþÀÇ Á¶Á÷.
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • cellular pole
    ¼¼Æ÷ ±Ø
    ¼¼Æ÷ÀÇ ÃàÀÇ ¾î´À ÇÑÂÊ ³¡ºÎºÐ. ¼¼Æ÷ÀÇ »ó¹ÝµÈ ºÐ¸®ÇÐÀû ¼ºÁúÀ» °¡ Áø µÎ Á¡ ÁßÀÇ Çϳª.
  • cellular proliferative layer
    ¼¼Æ÷¼º Áõ½ÄÃþ
    ¼¼Æ÷ÀÇ µ¿ÀÏÇüÅÂÀÇ Àç»ý»ê ¶Ç´Â Áõ½ÄÃþ.
  • cellular radiobiology
    ¼¼Æ÷ ¹æ»ç¼± »ý¹°ÇÐ
    ±¤¼±, Àڿܼ±, Àü¸®¹æ»ç¼±ÀÇ Á¶Á÷, ¼¼Æ÷¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¿¬±¸´ë»óÀ¸·Î ÇÑ °úÇÐÀÇ ÇÑ ºÐ¾ß.
  • cellular retinoid acid-binding protein
    ¼¼Æ÷³» ·¹Æ¼³ëÀ̵å»ê °áÇÕ ´Ü¹é
  • cellular sensitivity
    ¼¼Æ÷ °¨¼ö¼º
    ¼¼Æ÷°¡ °¨¼ö¼ºÀÌ ÀÖ´Â »óÅ ¶Ç´Â ¼ºÁú·Î¼­, Àڱؿ¡ ´ëÇØ¼­ ºñÁ¤»óÀûÀ¸·Î ¹ÝÀÀÇϰųª ¶Ç´Â ºü¸£°í ¿¹¹ÎÇÏ°Ô ¹ÝÀÀÇÏ´Â »óŸ¦ ³ªÅ¸³»´Â µ¥ Á¾Á¾ »ç¿ëµÈ´Ù.
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • cell cycle-non specific
    ¼¼Æ÷ Áֱ⠺ñƯÀ̼º Á¦Á¦
  • donor-specific phage
    °ø¿©±Õ ƯÀÌ ÆÄÁö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
adoptive immunity <immunology> Immunity to disease or infection conferred on a previously non-immune individual by transferring lymphocytes from a previously immune individual to the non-immune individual.
(15 Jan 1998)
allograft immunity <immunology> The recipient's immune system rejects tissue grafted from a genetically dissimilar donor (of the same species) and stages an immune attack against it.
(09 Oct 1997)
antiviral immunity Immunity resulting from virus infection, either naturally acquired or produced by intentional vaccination; compared to some bacterial immunity's, it is of relatively long duration, but this may be the result of infection-immunity rather than being peculiar to virus infection per se, since it occurs also in bacterial immunity after infections such as typhoid fever.
(05 Mar 2000)
artificial active immunity See: acquired immunity.
(05 Mar 2000)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
bacteriophage immunity The state induced in a bacterium by lysogenization, the lysogenic bacterium being insusceptible to further lysogenization or to a lytic cycle by a superinfecting bacteriophage, in contradistinction to bacteriophage resistance.
(05 Mar 2000)
general immunity Immunity associated with widely diffused mechanisms that tend to protect the body as a whole, as compared with local immunity.
(05 Mar 2000)
maternal immunity <epidemiology> Immunity for a neonate provided by IgG antibody generated by a mother and passed across the placenta to the unborn offspring. This provides short lived protection (with a typical half life of 3-6 months) to the neonate. Also known as immunity.
(05 Dec 1998)
passive immunity <immunology> Immunity acquired by the transfer from another animal of antibody or sensitised lymphocytes. Passive transfer of antibody from mother to offspring is important for immune defense during the perinatal period.
(18 Nov 1997)
relative immunity A modified, not completely effective resistance that results when there is a sort of "fluctuating equilibrium" between the defense mechanisms of the host and the infective agent.
(05 Mar 2000)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
concomitant immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
herd immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
humoral immunity <immunology> A form of immunity whereby B lymphocytes and plasma cells produce antibodies to foreign agents (antigens) and stimulate T lymphocytes to attack them (cellular immunity).
These antibodies also stimulate the release of chemical mediators (for example interferon, complement) which enhance antigen destruction.
(06 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á